KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Total Non-Current Liabilities (2016 - 2025)

Astrazeneca (AZN) has 3 years of Total Non-Current Liabilities data on record, last reported at $34.7 billion in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 1.59% year-over-year to $34.7 billion; the TTM value through Dec 2025 reached $34.7 billion, down 1.59%, while the annual FY2025 figure was $34.7 billion, 1.59% down from the prior year.
  • Total Non-Current Liabilities reached $34.7 billion in Q4 2025 per AZN's latest filing, down from $35.3 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $35.3 billion in Q4 2024 and bottomed at $31.4 billion in Q4 2023.
  • Average Total Non-Current Liabilities over 3 years is $33.8 billion, with a median of $34.7 billion recorded in 2025.
  • Peak YoY movement for Total Non-Current Liabilities: rose 12.37% in 2024, then fell 1.59% in 2025.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $31.4 billion in 2023, then rose by 12.37% to $35.3 billion in 2024, then decreased by 1.59% to $34.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $34.7 billion in Q4 2025, $35.3 billion in Q4 2024, and $31.4 billion in Q4 2023.